| Literature DB >> 24688681 |
Georgios Skretas1, Fragiskos N Kolisis2.
Abstract
Traditional metabolic engineering analyzes biosynthetic and physiological pathways, identifies bottlenecks, and makes targeted genetic modifications with the ultimate goal of increasing the production of high-value products in living cells. Such efforts have led to the development of a variety of organisms with industrially relevant properties. However, there are a number of cellular phenotypes important for research and the industry for which the rational selection of cellular targets for modification is not easy or possible. In these cases, strain engineering can be alternatively carried out using "inverse metabolic engineering", an approach that first generates genetic diversity by subjecting a population of cells to a particular mutagenic process, and then utilizes genetic screens or selections to identify the clones exhibiting the desired phenotype. Given the availability of an appropriate screen for a particular property, the success of inverse metabolic engineering efforts usually depends on the level and quality of genetic diversity which can be generated. Here, we review classic and recently developed combinatorial approaches for creating such genetic diversity and discuss the use of these methodologies in inverse metabolic engineering applications.Entities:
Keywords: genetic engineering; genetic screening; inverse metabolic engineering; microbes; mutagenesis
Year: 2013 PMID: 24688681 PMCID: PMC3962077 DOI: 10.5936/csbj.201210021
Source DB: PubMed Journal: Comput Struct Biotechnol J ISSN: 2001-0370 Impact factor: 7.271
Combinatorial genome engineering approaches which have been applied to inverse metabolic engineering applications.
| Method | Targeted cellular component | Target organism | Engineered phenotype | References |
|---|---|---|---|---|
| Spontaneous chromosomal mutagenesis | Chromosome |
| Ethanol and isobutanol tolerance; D-lactate, and hard-to-express protein production |
[ |
|
| Xylose consumption |
[ | ||
|
| 1,3-propanediol production |
[ | ||
|
| ||||
| Chromosomal mutagenesis using chemical mutagens or mutator genes | Chromosome |
| isobutanol, membrane protein, and full-length IgG production |
[ |
|
| ||||
| Transposon mutagenesis | All individual chromosomal genes |
| Biomass, lycopene, and recombinant membrane protein production |
[ |
|
| Riboflavin production |
[ | ||
|
| Poly-3-hydroxybutyrate production |
[ | ||
|
| Isoprenoid production |
[ | ||
|
| ||||
| Genomic libraries and related approaches (individual gene overexpression libraries, CoGeLs) | Chromosomal fragments |
| Acetate, glutamate, butanol, antibiotic and toxin tolerance; lycopene and membrane protein production |
[ |
|
| Alcohol tolerance and production; galactose fermentation |
[ | ||
|
| Butyrate tolerance |
[ | ||
|
| ||||
| Global transcription machinery engineering (gTME) | General sigma factor σ70, stationary phase sigma factor σS, RNA polymerase α subunit, cAMP receptor protein (CRP), histone-like nucleoid structuring protein H-NS, H-NS-interacting haemolysin expression modulating protein Hha, |
| Ethanol, butanol, isobutanol, pentanol, 3-pentanol, acetate, butyrate, high osmolarity, and SDS tolerance; lycopene, L-tyrosine, and hyaluronic acid production |
[ |
| Transcription factor Spt15p and TATA-binding protein Taf25p |
| Ethanol tolerance and production; xylose fermentation; corn cob acid hydrolysate tolerance |
[ | |
| General sigma factor RpoD |
| lactic acid and hydrochloric acid tolerance |
[ | |
|
| ||||
| Libraries of artificial zinc fingers | Zinc finger domains fused to transcriptional activators, repressors or without fusion partner |
| Tolerance to heat and osmotic stress; ketoconazole resistance |
[ |
| Mouse neuroblastoma cells | Neurogenesis, differentiation of neuroblasts to osteoblasts, proliferation rate |
[ | ||
|
| Tolerance to butanol, heat, cold, and osmotic stress |
[ | ||
|
| ||||
| Multiplex automated genome engineering (MAGE) | Multiple rationally selected genomic loci |
| Lycopene and indigo production; incorporation of artificial amino acids |
[ |
|
| ||||
| Trackable multiplex recombineering (TRMR) | >95% of all individual |
| Tolerance to salicin, D-fucose, methylglyoxal, valine, acetate and lignocellulosic hydrolysate |
[ |
|
| ||||
| Ribosome engineering | Ribosomal components or RNA polymerase subunits |
| Actinorhodin, fredericamycin, formycin, actinomycin, piperidamycin production |
[ |
|
| Amylase and protease production |
[ | ||
|
| Resistance to toluene, |
[ | ||
|
| ||||
| Genome shuffling | Chromosome |
| Tylosin production |
[ |
| A strain of | Tolerance to lactic acid |
[ | ||
|
| Degradation of pentachlorophenol |
[ | ||
|
| Butanol and antibiotic tolerance |
[ | ||
|
| Ethanol production |
[ | ||
Figure 1Schematic representation of the MAGE approach. First, specific genes/genomic locations known/suspected to be involved in a particular cellular phenotype are targeted for modification. Then, synthetic oligonucleotides that introduce insertions, deletions, missense mutations, or other types of genetic lesions are synthesized and introduced into the target cell host by electroporation. Subsequently, the action of the λ Red recombinase system assists the introduction of the designed lesions into the target genomic loci. Finally, the beneficial mutations are selected and enriched by performing cycles of genetic screening or selection. The beneficial genomic alterations can be readily identified by DNA sequencing of the targeted genomic locations.